JNJ-37822681 has been used in trials studying the treatment of Schizophrenia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Tetrabenazine | The risk or severity of adverse effects can be increased when JNJ-37822681 is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when JNJ-37822681 is combined with Deutetrabenazine. |
| Apomorphine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with JNJ-37822681. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with JNJ-37822681. |
| Levodopa | The therapeutic efficacy of Levodopa can be decreased when used in combination with JNJ-37822681. |
| Rotigotine | The therapeutic efficacy of Rotigotine can be decreased when used in combination with JNJ-37822681. |
| Piribedil | The therapeutic efficacy of Piribedil can be decreased when used in combination with JNJ-37822681. |
| Cabergoline | The therapeutic efficacy of Cabergoline can be decreased when used in combination with JNJ-37822681. |
| Dihydroergotamine | The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with JNJ-37822681. |
| Lisuride | The therapeutic efficacy of Lisuride can be decreased when used in combination with JNJ-37822681. |
| Fenoldopam | The therapeutic efficacy of Fenoldopam can be decreased when used in combination with JNJ-37822681. |
| Ergoloid mesylate | The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with JNJ-37822681. |
| Pergolide | The therapeutic efficacy of Pergolide can be decreased when used in combination with JNJ-37822681. |
| Aripiprazole | The therapeutic efficacy of Aripiprazole can be decreased when used in combination with JNJ-37822681. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with JNJ-37822681. |
| Brexpiprazole | The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with JNJ-37822681. |
| Dihydroergocornine | The therapeutic efficacy of Dihydroergocornine can be decreased when used in combination with JNJ-37822681. |
| Dopexamine | The therapeutic efficacy of Dopexamine can be decreased when used in combination with JNJ-37822681. |
| Dihydrexidine | The therapeutic efficacy of Dihydrexidine can be decreased when used in combination with JNJ-37822681. |
| Dihydroergocryptine | The therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with JNJ-37822681. |
| Metergoline | The therapeutic efficacy of Metergoline can be decreased when used in combination with JNJ-37822681. |
| Ropinirole | The therapeutic efficacy of Ropinirole can be decreased when used in combination with JNJ-37822681. |
| Benzatropine | The risk or severity of adverse effects can be increased when JNJ-37822681 is combined with Benzatropine. |
| Pramipexole | The therapeutic efficacy of Pramipexole can be decreased when used in combination with JNJ-37822681. |
| Epicriptine | The therapeutic efficacy of Epicriptine can be decreased when used in combination with JNJ-37822681. |